Aclaris Therapeutics to Participate in Upcoming Investor Conferences
27 August 2021 - 6:01AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
management will participate in the following upcoming investor
conferences:
- H.C. Wainwright 23rd Annual Global Investment
Conference. On Monday, September 13, 2021 at 7:00 a.m. ET,
Dr. Neal Walker, the President and CEO of Aclaris, will virtually
present a company overview. Management will be available September
13th throughout the day for virtual one-on-one meetings.
- 2021 Cantor Virtual Global Healthcare
Conference. On Monday, September 27, 2021 at 9:20 a.m. ET,
Dr. Walker will participate in a virtual fireside chat. Management
will be available September 27th throughout the day for virtual
one-on-one meetings.
A live webcast of the presentation and fireside chat may be
accessed through the “Events” page of the “Investors” section of
Aclaris’ website, www.aclaristx.com. Each webcast will be archived
for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Aclaris
Contactinvestors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2024 to May 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From May 2023 to May 2024